Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish Saxena

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of the American Heart Association|February 7, 2024
Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial)David J Collier, Mike Taylor, Thomas Godec, et al.
Journal of the American Heart Association|December 23, 2016
Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined HypertensionChristian Ott, Melvin D Lobo, Paul A Sobotka, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
American Heart Journal|August 10, 2018
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trialOmar Mukhtar, Joseph Cheriyan, John R Cockcroft, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
European Journal of Heart Failure|August 11, 2025
Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registryStephen J Greene, Andrew J Sauer, Michael Böhm, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of the American Heart Association|February 7, 2024
Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial)David J Collier, Mike Taylor, Thomas Godec, et al.
Journal of the American Heart Association|December 23, 2016
Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined HypertensionChristian Ott, Melvin D Lobo, Paul A Sobotka, et al.
JAMA Cardiology|November 9, 2022
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical TrialMichel Azizi, Felix Mahfoud, Michael A Weber, et al.
Journal of Human Hypertension|May 25, 2021
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO studyManish Saxena, Roland E Schmieder, Ajay J Kirtane, et al.
Circulation|October 26, 2023
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial ProgramMichel Azizi, Andrew S P Sharp, Naomi D L Fisher, et al.
Lancet (London, England)|May 28, 2018
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialMichel Azizi, Roland E Schmieder, Felix Mahfoud, et al.
American Heart Journal|August 10, 2018
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trialOmar Mukhtar, Joseph Cheriyan, John R Cockcroft, et al.
JAMA|February 28, 2023
Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical TrialMichel Azizi, Manish Saxena, Yale Wang, et al.
European Journal of Heart Failure|August 11, 2025
Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registryStephen J Greene, Andrew J Sauer, Michael Böhm, et al.
JAMA Cardiology|February 28, 2023
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO TrialsAjay J Kirtane, Andrew S P Sharp, Felix Mahfoud, et al.
Pageof 7